Single-agent ibrutinib in relapsed or refractory follicular lymphoma: a phase 2 consortium trial

Most patients with follicular lymphoma (FL) experience multiple relapses necessitating subsequent lines of therapy. Ibrutinib, a Bruton tyrosine kinase (BTK) inhibitor approved for the treatment of several B-cell malignancies, showed promising activity in FL in a phase 1 study. We report the results...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Blood
Main Authors: Bartlett, Nancy L., Costello, Brian A., LaPlant, Betsy R., Ansell, Stephen M., Kuruvilla, John G., Reeder, Craig B., Thye, Lim S., Anderson, Daniel M., Krysiak, Kilannin, Ramirez, Cody, Qi, Jing, Siegel, Barry A., Griffith, Malachi, Griffith, Obi L., Gomez, Felicia, Fehniger, Todd A.
Formato: Artigo
Idioma:Inglês
Publicado em: American Society of Hematology 2018
Assuntos:
Clinical Trials and Observations
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5757691/
https://ncbi.nlm.nih.gov/pubmed/29074501
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2017-09-804641
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados